UNSPSC 51332853: Fluphenazine maleate

This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 97151695PW. European Medicines Agency schedules Fluphenazine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22373. Fluphenazine maleate generally arises in the molecular formula C22H26F3N3OS.C4H4O4. The term 'fluphenazine maleate' is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule fluphenazine maleate under HS 29343090 and SITC 51578.

As of Q4 2014, FLUPHENAZINE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)N(C3CC(CCC3S2)C(F)(F)F)CCCN4CCN(CC4)CCO.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51332853 Fluphenazine maleate, a Commodity code, nominally addresses a single antipsychotic pharmaceutical agent, but the recent state and local opportunities tagged under it reflect broader pharmaceutical procurement — naloxone distribution, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription program design. State and local governments soliciting under this code or related pharmaceutical commodities are primarily seeking large-volume distribution of naloxone and opioid-reversal products, generic pharmaceuticals through cooperative purchasing arrangements, and pilot programs to bypass traditional pharmacy benefit managers and wholesalers. The issuing bodies include county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances, with purchasing driven by community health initiatives, opioid-response funding, and cost-containment objectives for pharmacy benefit programs.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through an electronic bidding process with quarterly deliveries, due July 26, 2023 (note: date appears inconsistent with posting date). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capability information for a Therapeutic Pharmacy Initiative direct-to-manufacturer model, signaling a shift toward alternative contracting outside traditional PBM channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota, Oregon, and other participating jurisdictions, with proposals due March 26, 2026 and awards effective July 1, 2026. All three procurements required submission through electronic procurement portals and included insurance, compliance, and supply chain security certifications.